Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


Promoting growth

Long-term partner for start-ups

We have already accompanied over 100 start-up projects. We usually acquire a minority share in the resulting companies.

We continue to support our portfolio companies on their growth trajectory and manage our shares as profitably as possible until exit – or, in the case of floatation or takeovers by listed companies, beyond.

We distribute most of our revenues from the sale of equity and shares to the LifeScience Foundation, which in turn makes them available to its endowing institutes as research grants

Current shareholdings

[Translate to English:]

AI-powered precision diagnostics for pathology

Peptide active ingredients for the treatment of highly metastatic carcinomas

Therapeutics against various autoimmune disorders

[Translate to English:]

Design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases

[Translate to English:]

Digital health startup developing and operating a dynamic consent platform to connect data and material donors with researchers and clinicians

Decision support platform that helps dentists detect pathologies and restorations on dental x-ray images

[Translate to English:]

Next level for molecular diagnostics in human skin to improve patients‘ lives and clinical practice in dermatology

[Translate to English:]

Discovery and development of new chemical entities for treatment of acute and chronic liver diseases

[Translate to English:]

Novel cell screening technologies for drug development

[Translate to English:]

Qualitative and quantitative measurement of the biological decomposition of toxic waste (contaminated soil)

[Translate to English:]

Novel optoacoustic imaging technology

[Translate to English:]

Development of personalized T cell immunotherapies with a focus on haematological malignancies
Acquisition of Trianta in January 2014

[Translate to English:]

Medtherm GmbH

Advisory service for the application of hyperthermia therapy

[Translate to English:]

Platform to digitize healthcare for all poor countries

[Translate to English:]

Development of small molecules using an innovative endogenous protective mechanism. Primary focus is the development of a first-in-class oral drug for…

[Translate to English:]

Photoionization mass spectrometry for the direct analysis of complex organic gasses and solids

[Translate to English:]

Diagnosing cortical bone health with ultrasound

Development of ATMPs based on recombinase driven error-free genome editing for eradication of life-threatening virus infection

[Translate to English:]

Developing and commercializing ferroptosis modulators for therapeutic use

[Translate to English:]

Development of T cell receptors (TCRs) for T cell therapy of cancer 

[Translate to English:]

Development of cancer therapies based on tubulysins

[Translate to English:]

Development of pharmaceutical therapies for the treatment of airways-related diseases
Acquisition of Activaero in March 2014

Former Holdings

    • Activaero GmbH

    • Alerion

    • BigChem GmbH

    • Biomax AG

    • Bioregeneration GmbH

    • BITZ GmbH

    • Canopy Biosciences

    • Clueda AG

    • eADMET GmbH

    • Encepharm GmbH

    • Genomatix GmbH

    • Inamed GmbH

    • NanoRepro GmbH

    • Spero Therapeutics LLC

    • SurgVision B.V.

    • Trianta Immunotherapies GmbH

    • TRION Pharma GmbH

    • Vakzine Projekt Management GmbH

    • WBC Drug Delivery Technologies

    • Zellkraftwerk GmbH

    • WBC Drug Delivery Technologies